Antimicrobial agent resistance in mycobacteria: molecular genetic insights

The primary theme emerging from molecular genetic work conducted with Mycobacterium tuberculosis and several other mycobacterial species is that resistance is commonly associated with simple nucleotide alterations in target chromosomal genes rather than with acquisition of new genetic elements encoding antibiotic-altering enzymes. Mutations in an 81-bp region of the gene (rpoB) encoding the beta subunit of RNA polymerase account for rifampin resistance in 96% of M. tuberculosis and many Mycobacterium leprae isolates. Streptomycin resistance in about one-half of M. tuberculosis isolates is associated with missense mutations in the rpsL gene coding for ribosomal protein S12 or nucleotide substitutions in the 16S rRNA gene (rrs). Mutations in the katG gene resulting in catalase-peroxidase amino acid alterations nad nucleotide substitutions in the presumed regulatory region of the inhA locus are repeatedly associated with isoniazid-resistant M. tuberculosis isolates. A majority of fluoroquinolone-resistant M. tuberculosis isolates have amino acid substitutions in a region of the DNA gyrase A subunit homologous to a conserved fluoroquinolone resistance-determining region. Multidrug-resistant isolates of M. tuberculosis arise as a consequence of sequential accumulation of mutations conferring resistance to single therapeutic agents. Molecular strategies show considerable promise for rapid detection of mutations associated with antimicrobial resistance. These approaches are now amenable to utilization in an appropriately equipped clinical microbiology laboratory.

[1]  D van Soolingen,et al.  Characterization of the catalase-peroxidase gene (katG) and inhA locus in isoniazid-resistant and -susceptible strains of Mycobacterium tuberculosis by automated DNA sequencing: restricted array of mutations associated with drug resistance. , 1996, The Journal of infectious diseases.

[2]  C. Benson,et al.  Disease due to the Mycobacterium avium complex in patients with AIDS: epidemiology and clinical syndrome. , 1994, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[3]  J. Kraut,et al.  Crystal structure of a complex between electron transfer partners, cytochrome c peroxidase and cytochrome c. , 1993, Science.

[4]  D. Young,et al.  Molecular mechanisms of isoniazid: a drug at the front line of tuberculosis control. , 1993, Trends in microbiology.

[5]  L. Brakier-Gingras,et al.  Mutations in the 915 region of Escherichia coli 16S ribosomal RNA reduce the binding of streptomycin to the ribosome. , 1991, Nucleic acids research.

[6]  R. Shafer,et al.  Temporal trends and transmission patterns during the emergence of multidrug-resistant tuberculosis in New York City: a molecular epidemiologic assessment. , 1995, The Journal of infectious diseases.

[7]  F. Portaels,et al.  Geographically distinct isolates of Mycobacterium leprae exhibit no genotypic diversity by restriction fragment‐length polymorphism analysis , 1990, Molecular microbiology.

[8]  T. Wilson,et al.  Effect of inhA and katG on isoniazid resistance and virulence of Mycobacterium bovis , 1995, Molecular microbiology.

[9]  J. Tokars,et al.  Current practices in mycobacteriology: results of a survey of state public health laboratories , 1993, Journal of clinical microbiology.

[10]  D. Mitchison,et al.  In vitro activity of new rifamycins against rifampicin-resistant M. tuberculosis and MAIS-complex mycobacteria. , 1987, Tubercle.

[11]  E. Peets,et al.  Effect of Ethambutol on Nucleic Acid Metabolism in Mycobacterium smegmatis and Its Reversal by Polyamines and Divalent Cations , 1965, Journal of bacteriology.

[12]  J. Mendell,et al.  Identification of two point mutations and a one base deletion in exon 19 of the dystrophin gene by heteroduplex formation. , 1993, Human molecular genetics.

[13]  K. Sepkowitz,et al.  Tuberculosis symposium: emerging problems and promise. , 1993, The Journal of infectious diseases.

[14]  B. U. Bowman,et al.  Evidence for the generation of active oxygen by isoniazid treatment of extracts of Mycobacterium tuberculosis H37Ra , 1985, Antimicrobial Agents and Chemotherapy.

[15]  R. Drmanac,et al.  Sequencing of megabase plus DNA by hybridization: theory of the method. , 1989, Genomics.

[16]  R. Shepherd,et al.  A new synthetic compound with antituberculous activity in mice: ethambutol (dextro-2,2'-(ethylenediimino)-di-l-butanol). , 2015, The American review of respiratory disease.

[17]  J. Douglass,et al.  A ribosomal gene mutation in streptomycin-resistant Mycobacterium tuberculosis isolates. , 1993, The Journal of infectious diseases.

[18]  B. Bloom,et al.  Tuberculosis Pathogenesis, Protection, and Control , 1994 .

[19]  K. Sepkowitz,et al.  Trends in the susceptibility of tuberculosis in New York City, 1987-1991. New York City Area Tuberculosis Working Group. , 1994, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[20]  G. Churchward,et al.  Cloning and sequence analysis of the rpsL and rpsG genes of Mycobacterium smegmatis and characterization of mutations causing resistance to streptomycin , 1994, Journal of bacteriology.

[21]  S. Cole,et al.  Molecular basis of rifampin resistance in Mycobacterium leprae , 1993, Antimicrobial Agents and Chemotherapy.

[22]  M. Felten,et al.  Drug-resistant tuberculosis: laboratory issues. World Health Organization recommendations. , 1994, Tubercle and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[23]  J. Sacchettini,et al.  Crystal structure and function of the isoniazid target of Mycobacterium tuberculosis , 1995, Science.

[24]  A. Telenti,et al.  Mutation position and type of substitution in the beta-subunit of the RNA polymerase influence in-vitro activity of rifamycins in rifampicin-resistant Mycobacterium tuberculosis. , 1995, The Journal of antimicrobial chemotherapy.

[25]  R. Chaisson,et al.  Two controlled trials of rifabutin prophylaxis against Mycobacterium avium complex infection in AIDS. , 1993, The New England journal of medicine.

[26]  W. Schaefer,et al.  Studies on isoniazid and tubercle bacilli. III. The isolation, drug-susceptibility, and catalase-testing of tubercle bacilli from isoniazid-treated patients. , 1954, American review of tuberculosis.

[27]  Recommendations on prophylaxis and therapy for disseminated Mycobacterium avium complex for adults and adolescents infected with human immunodeficiency virus. U.S. Public Health Service Task Force on Prophylaxis and Therapy for Mycobacterium avium Complex. , 1993, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[28]  O. Kafri,et al.  Mycobacteria possess a surprisingly small number of ribosomal RNA genes in relation to the size of their genome. , 1986, Biochemical and biophysical research communications.

[29]  L. Paulin,et al.  SPECIFIC INHIBITION OF SPERMIDINE SYNTHASE FROM MYCOBACTERIA BY ETHAMBUTOL , 1983, The Lancet.

[30]  G. Canetti Present aspects of bacterial resistance in tuberculosis. , 1965, The American review of respiratory disease.

[31]  P. Loewen,et al.  Molecular characterization of three mutations in katG affecting the activity of hydroperoxidase I of Escherichia coli. , 1990, Biochemistry and cell biology = Biochimie et biologie cellulaire.

[32]  C. Cech,et al.  On the mechanism of rifampicin inhibition of RNA synthesis. , 1978, The Journal of biological chemistry.

[33]  S. Cole,et al.  Nucleotide sequence of the first cosmid from the Mycobacterium leprae genome project: structure and function of the Rif‐Str regions , 1993, Molecular microbiology.

[34]  J. Kilburn,et al.  Susceptibility of Mycobacterium tuberculosis to pyrazinamide and its relationship to pyrazinamidase activity , 1983, Antimicrobial Agents and Chemotherapy.

[35]  T. Frieden,et al.  Emergence of fluoroquinolone-resistant tuberculosis in New York City , 1995, The Lancet.

[36]  Horsburgh Cr Mycobacterium avium complex infection in the acquired immunodeficiency syndrome. , 1991, The New England journal of medicine.

[37]  V. Jarlier,et al.  Characterization of mutations in Mycobacterium smegmatis involved in resistance to fluoroquinolones , 1994, Antimicrobial Agents and Chemotherapy.

[38]  Expanded tuberculosis surveillance and tuberculosis morbidity--United States, 1993. , 1994, MMWR. Morbidity and mortality weekly report.

[39]  Earl B. Herr,et al.  CHEMICAL AND PHYSICAL CHARACTERIZATION OF CAPREOMYCIN , 1966, Annals of the New York Academy of Sciences.

[40]  A. Quémard,et al.  Isoniazid inhibition of mycolic acid synthesis by cell extracts of sensitive and resistant strains of Mycobacterium aurum , 1991, Antimicrobial Agents and Chemotherapy.

[41]  P. Davidson,et al.  Cross-resistance in M. tuberculosis to kanamycin, capreomycin and viomycin. , 1977, Tubercle.

[42]  J. Rosner Susceptibilities of oxyR regulon mutants of Escherichia coli and Salmonella typhimurium to isoniazid , 1993, Antimicrobial Agents and Chemotherapy.

[43]  C. Gross,et al.  Characterization of the pleiotropic phenotypes of rifampin-resistant rpoB mutants of Escherichia coli , 1989, Journal of bacteriology.

[44]  A. Telenti,et al.  Evaluation of the rpoB gene in rifampicin-susceptible and -resistant Mycobacterium avium and Mycobacterium intracellulare. , 1994, The Journal of antimicrobial chemotherapy.

[45]  B. U. Bowman,et al.  Peroxidase-mediated oxidation of isoniazid , 1985, Antimicrobial Agents and Chemotherapy.

[46]  G. Middlebrook Isoniazid-resistance and catalase activity of tubercle bacilli; a preliminary report. , 1954, American review of tuberculosis.

[47]  E. L. Armstrong,et al.  Effects of Ethambutol on Phospholipid Metabolism in Mycobacterium smegmatis , 1981, Antimicrobial Agents and Chemotherapy.

[48]  A. Telenti,et al.  Rapid Mycobacterium species assignment and unambiguous identification of mutations associated with antimicrobial resistance in Mycobacterium tuberculosis by automated DNA sequencing. , 1995, Archives of pathology & laboratory medicine.

[49]  R. Wallace,,et al.  Activities of four macrolides, including clarithromycin, against Mycobacterium fortuitum, Mycobacterium chelonae, and M. chelonae-like organisms , 1992, Antimicrobial Agents and Chemotherapy.

[50]  A. Aufderheide,et al.  Identification of Mycobacterium tuberculosis DNA in a pre-Columbian Peruvian mummy. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[51]  D B Goodin,et al.  Identification by ENDOR of Trp191 as the free-radical site in cytochrome c peroxidase compound ES. , 1989, Science.

[52]  G. Hatfull,et al.  Mycobacterium smegmatis RNA polymerase: DNA supercoiling, action of rifampicin and mechanism of rifampicin resistance , 1993, Molecular microbiology.

[53]  M. Chengappa Antimicrobial Agents and Susceptibility Testing , 1990 .

[54]  S. Cole,et al.  Streptomycin resistance in mycobacteria , 1994, Antimicrobial Agents and Chemotherapy.

[55]  W. Black,et al.  Mutations in the catalase-peroxidase gene from isoniazid-resistant Mycobacterium tuberculosis isolates. , 1994, The Journal of infectious diseases.

[56]  B C Finzel,et al.  Crystal structure of yeast cytochrome c peroxidase refined at 1.7-A resolution. , 1984, The Journal of biological chemistry.

[57]  M. Iseman,et al.  PITFALLS IN THE CARE OF PATIENTS WITH TUBERCULOSIS: COMMON ERRORS AND THEIR ASSOCIATION WITH THE ACQUISITION OF DRUG RESISTANCE , 1993, JAMA.

[58]  K. Suzuki,et al.  [In vitro activities of new rifamycin derivatives against Mycobacterium tuberculosis and M. avium complex]. , 1990, Kekkaku : [Tuberculosis].

[59]  E. Böttger,et al.  Genetic alterations in streptomycin-resistant Mycobacterium tuberculosis: mapping of mutations conferring resistance , 1994, Antimicrobial Agents and Chemotherapy.

[60]  T. Frieden,et al.  The emergence of drug-resistant tuberculosis in New York City. , 1993, The New England journal of medicine.

[61]  T. Whittam,et al.  Is Mycobacterium tuberculosis 15,000 years old? , 1994, The Journal of infectious diseases.

[62]  D. Young,et al.  Transformation with katG restores isoniazid‐sensitivity in Mycobacterium tuberculosis isolates resistant to a range of drug concentrations , 1993, Molecular microbiology.

[63]  T. T. Hok A COMPARATIVE STUDY OF THE SUSCEPTIBILITY TO ETHIONAMIDE, THIOSEMICARBAZONE, AND ISONIAZID OF TUBERCLE BACILLI FROM PATIENTS NEVER TREATED WITH ETHIONAMIDE OR THIOSEMICARBAZONE. , 1964, The American review of respiratory disease.

[64]  H. Noller Structure of ribosomal RNA. , 1984, Annual review of biochemistry.

[65]  W. Bains,et al.  A novel method for nucleic acid sequence determination. , 1988, Journal of theoretical biology.

[66]  L. Heifets,et al.  Does pyrazinoic acid as an active moiety of pyrazinamide have specific activity against Mycobacterium tuberculosis? , 1989, Antimicrobial Agents and Chemotherapy.

[67]  H. Noller,et al.  Mutations in ribosomal proteins S4 and S12 influence the higher order structure of 16 S ribosomal RNA. , 1989, Journal of molecular biology.

[68]  D. Persing,et al.  Detection of a genetic locus encoding resistance to rifampin in mycobacterial cultures and in clinical specimens. , 1994, Diagnostic microbiology and infectious disease.

[69]  K. Takayama,et al.  Effect of Isoniazid on the In Vivo Mycolic Acid Synthesis, Cell Growth, and Viability of Mycobacterium tuberculosis , 1972, Antimicrobial Agents and Chemotherapy.

[70]  H. Bergler,et al.  Sequences of the envM gene and of two mutated alleles in Escherichia coli. , 1992, Journal of general microbiology.

[71]  S. Cole,et al.  Missense mutations in the catalase‐peroxidase gene, katG, are associated with isoniazid resistance in Mycobacterium tuberculosis , 1995, Molecular microbiology.

[72]  M. Lanéelle,et al.  Mycolic acid synthesis by Mycobacterium aurum cell-free extracts. , 1990, Biochimica et biophysica acta.

[73]  D. Mitchison,et al.  A comparison of the virulence in guinea-pigs of South Indian and British tubercle bacilli. , 1960, Tubercle.

[74]  G. Ellard Combined treatment for lepromatous leprosy. , 1980, Leprosy review.

[75]  J. Musser,et al.  Characterization by automated DNA sequencing of mutations in the gene (rpoB) encoding the RNA polymerase beta subunit in rifampin-resistant Mycobacterium tuberculosis strains from New York City and Texas , 1994, Journal of clinical microbiology.

[76]  H. Wittmann,et al.  Ribosomal proteins. 33. Location of amino-acid replacements in protein S12 isolated from Escherichia coli mutants resistant to streptomycin. , 1972, Journal of molecular biology.

[77]  L. Paulin,et al.  Specific inhibition of spermidine synthesis in Mycobacteria spp. by the dextro isomer of ethambutol , 1985, Antimicrobial Agents and Chemotherapy.

[78]  L. Heifets,et al.  MICs and MBCs of Win 57273 against Mycobacterium avium and M. tuberculosis , 1990, Antimicrobial Agents and Chemotherapy.

[79]  F. Cockerill,et al.  Rapid identification of a point mutation of the Mycobacterium tuberculosis catalase-peroxidase (katG) gene associated with isoniazid resistance. , 1995, The Journal of infectious diseases.

[80]  H. Noller,et al.  Mutations in 16S ribosomal RNA disrupt antibiotic–RNA interactions. , 1989, The EMBO journal.

[81]  Harry F. Noller,et al.  Interaction of antibiotics with functional sites in 16S ribosomal RNA , 1987, Nature.

[82]  B. Heym,et al.  Implications of multidrug resistance for the future of short-course chemotherapy of tuberculosis: a molecular study , 1994, The Lancet.

[83]  C. Loveday,et al.  A microtitre format point mutation assay: Application to the detection of drug resistance in human immunodeficiency virus type‐1 infected patients treated with zidovudine , 1992, Journal of medical virology.

[84]  T. Sekiya,et al.  Detection of polymorphisms of human DNA by gel electrophoresis as single-strand conformation polymorphisms. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[85]  D. Persing,et al.  Genotypic detection of Mycobacterium tuberculosis rifampin resistance: comparison of single-strand conformation polymorphism and dideoxy fingerprinting , 1995, Journal of clinical microbiology.

[86]  C. Shepard Statistical analysis of results obtained by two methods for testing drug activity against Mycobacterium leprae. , 1982, International journal of leprosy and other mycobacterial diseases : official organ of the International Leprosy Association.

[87]  D. Jamison,et al.  Disease Control Priorities in Developing Countries , 1993 .

[88]  C Summers,et al.  Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS). , 1989, Nucleic acids research.

[89]  S. Wellstood Diagnostic Mycobacteriology: Current Challenges and Technologies , 1993 .

[90]  L. Marsili,et al.  Biological activity of a new class of rifamycins. Spiro-piperidyl-rifamycins. , 1980, The Journal of antibiotics.

[91]  D. Persing,et al.  Direct genotypic detection of Mycobacterium tuberculosis rifampin resistance in clinical specimens by using single-tube heminested PCR , 1995, Journal of clinical microbiology.

[92]  A. Nagata,et al.  Organization of rRNA genes in Mycobacterium bovis BCG , 1987, Journal of bacteriology.

[93]  Christopher J. L. Murray,et al.  Tuberculosis: Commentary on a Reemergent Killer , 1992, Science.

[94]  E. L. Armstrong,et al.  Inhibition by Ethambutol of Mycolic Acid Transfer into the Cell Wall of Mycobacterium smegmatis , 1979, Antimicrobial Agents and Chemotherapy.

[95]  M. Daffé,et al.  Ethambutol inhibition of glucose metabolism in mycobacteria: a possible target of the drug , 1993, Antimicrobial Agents and Chemotherapy.

[96]  M. Cynamon,et al.  Drug Susceptibility in the Chemotherapy of Mycobacterial Infections , 1991 .

[97]  C. Gross,et al.  Mapping and sequencing of mutations in the Escherichia coli rpoB gene that lead to rifampicin resistance. , 1988, Journal of molecular biology.

[98]  F. Winder,et al.  Effects of ethionamide and isoxyl on mycolic acid synthesis in Mycobacterium tuberculosis BCG. , 1971, Journal of general microbiology.

[99]  A. Tsang,et al.  Use of pyrazinamidase activity on Mycobacterium tuberculosis as a rapid method for determination of pyrazinamide susceptibility , 1981, Antimicrobial Agents and Chemotherapy.

[100]  H. David,et al.  Some observations on the genetics of isoniazid resistance in the tubercle bacilli. , 1971, The American review of respiratory disease.

[101]  W. Mcdermott,et al.  Pyrazinamide susceptibility and amidase activity of tubercle bacilli. , 1967, The American review of respiratory disease.

[102]  W. Jacobs,et al.  inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. , 1994, Science.

[103]  A. Kochi,et al.  The global tuberculosis situation and the new control strategy of the World Health Organization. , 1991, Tubercle.

[104]  T. Sekiya,et al.  Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction. , 1989, Genomics.

[105]  Kevin M. De Cock,et al.  Tuberculosis: Pathogenesis, protection, and control - B. R. Bloom (editor). Washington, DC: American Society for Microbiology, 1994. xv + 637pp. Price @$57.50. ISBN 1-55581-072-1 , 1995 .

[106]  G. Bai,et al.  The rpsL gene and streptomycin resistance in single and multiple drug‐resistant strains of Mycobacterium tuberculosis , 1993, Molecular microbiology.

[107]  D. Snider,et al.  Nationwide survey of drug-resistant tuberculosis in the United States. , 1994, JAMA.

[108]  Shepard Cc Statistical analysis of results obtained by two methods for testing drug activity against Mycobacterium leprae. , 1982 .

[109]  Ernest Frederick Gale,et al.  The Molecular basis of antibiotic action , 1972 .

[110]  E. Böttger,et al.  Molecular basis of streptomycin resistance in Mycobacterium tuberculosis: alterations of the ribosomal protein S12 gene and point mutations within a functional 16S ribosomal RNA pseudoknot , 1993, Molecular microbiology.

[111]  M. Tsukamura,et al.  Therapeutic effect of a new antibacterial substance ofloxacin (DL8280) on pulmonary tuberculosis. , 2015, The American review of respiratory disease.

[112]  D. Rouse,et al.  The catalase-peroxidase of Mycobacterium intracellulare: nucleotide sequence analysis and expression in Escherichia coli. , 1992, Journal of general microbiology.

[113]  S T Cole,et al.  Characterization of the katG gene encoding a catalase-peroxidase required for the isoniazid susceptibility of Mycobacterium tuberculosis , 1993, Journal of bacteriology.

[114]  J. Grosset,et al.  Combined chemotherapy including rifabutin for rifampicin and isoniazid resistant pulmonary tuberculosis. G.E.T.I.M. (Group for the Study and Treatment of Resistant Mycobacterial Infection). , 1992, The European respiratory journal.

[115]  A. Telenti,et al.  Cloning and nucleotide sequence of Mycobacterium tuberculosis gyrA and gyrB genes and detection of quinolone resistance mutations , 1994, Antimicrobial Agents and Chemotherapy.

[116]  A. Telenti,et al.  Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis , 1993, The Lancet.

[117]  S. O’Brien,et al.  Detecting single base substitutions as heteroduplex polymorphisms. , 1992, Genomics.

[118]  P. Hopmans [Epidemiology of tuberculosis]. , 1960, Geneeskundige gids.

[119]  W. Beggs,et al.  Nonspecific Ionic Inhibition of Ethambutol Binding by Mycobacterium smegmatis , 1973, Antimicrobial Agents and Chemotherapy.

[120]  I. Orme,et al.  Drug-resistant strains of Mycobacterium tuberculosis exhibit a range of virulence for mice , 1995, Infection and immunity.

[121]  M. Roberts,et al.  Tetracycline resistance determinants in Mycobacterium and Streptomyces species , 1994, Antimicrobial Agents and Chemotherapy.

[122]  J. Kornblum,et al.  Catalase-peroxidase gene sequences in isoniazid-sensitive and -resistant strains of Mycobacterium tuberculosis from New York City. , 1993, The Journal of infectious diseases.

[123]  G. Högenauer,et al.  envM genes of Salmonella typhimurium and Escherichia coli , 1989, Journal of bacteriology.

[124]  M. J. Lefford The ethionamide sensitivity of British pre-treatment strains of Mycobacterium tuberculosis. , 1966, Tubercle.

[125]  E. Peets,et al.  MODE OF ACTION OF ETHAMBUTOL , 1962, Journal of bacteriology.

[126]  R. Wallace,,et al.  Identification of mutations in 23S rRNA gene of clarithromycin-resistant Mycobacterium intracellulare , 1994, Antimicrobial Agents and Chemotherapy.

[127]  R. Kajioka,et al.  Permeability Barrier to Rifampin in Mycobacteria , 1977, Antimicrobial Agents and Chemotherapy.

[128]  K. Khrapko,et al.  An oligonucleotide hybridization approach to DNA sequencing , 1989, FEBS letters.

[129]  J. T. Crawford,et al.  Characterization of rifampin-resistance in pathogenic mycobacteria , 1994, Antimicrobial Agents and Chemotherapy.

[130]  F. Barany Genetic disease detection and DNA amplification using cloned thermostable ligase. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[131]  D. Jabes,et al.  LM 427, a new spiropiperidylrifamycin: in vitro and in vivo studies. , 1983, The Journal of antibiotics.

[132]  D. Hooper,et al.  Quinolone antimicrobial agents , 1993 .

[133]  F. Winder,et al.  Inhibition by isoniazid of synthesis of mycolic acids in Mycobacterium tuberculosis. , 1970, Journal of general microbiology.

[134]  V. Jarlier,et al.  Selection of a gyrA mutant of Mycobacterium tuberculosis resistant to fluoroquinolones during treatment with ofloxacin. , 1994, The Journal of infectious diseases.

[135]  B. Leitinger,et al.  Protein EnvM is the NADH-dependent enoyl-ACP reductase (FabI) of Escherichia coli. , 1994, The Journal of biological chemistry.

[136]  C. Kovitz,et al.  Studies on isoniazid and tubercle bacilli. II. The growth requirements, catalase activities, and pathogenic properties of isoniazid-resistant mutants. , 1954, American review of tuberculosis.

[137]  Kenneth L. Beattie,et al.  Solid-phase gene assembly , 1991, Nature.

[138]  J. T. Crawford,et al.  The rpoB gene of Mycobacterium tuberculosis , 1994, Antimicrobial Agents and Chemotherapy.

[139]  A. Telenti,et al.  Direct, automated detection of rifampin-resistant Mycobacterium tuberculosis by polymerase chain reaction and single-strand conformation polymorphism analysis , 1993, Antimicrobial Agents and Chemotherapy.

[140]  K. Takayama,et al.  Inhibition of synthesis of arabinogalactan by ethambutol in Mycobacterium smegmatis , 1989, Antimicrobial Agents and Chemotherapy.

[141]  G. Bai,et al.  Molecular mechanisms of multiple drug resistance in clinical isolates of Mycobacterium tuberculosis. , 1995, The Journal of infectious diseases.

[142]  A controlled study of rifabutin and an uncontrolled study of ofloxacin in the retreatment of patients with pulmonary tuberculosis resistant to isoniazid, streptomycin and rifampicin. Hong Kong Chest Service/British Medical Research Council. , 1992, Tubercle and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[143]  S. Cole,et al.  The catalase—peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis , 1992, Nature.

[144]  L. Heifets,et al.  Clarithromycin minimal inhibitory and bactericidal concentrations against Mycobacterium avium. , 1992, The American review of respiratory disease.

[145]  S. Siddiqi,et al.  Evaluation of rapid radiometric method for drug susceptibility testing of Mycobacterium tuberculosis , 1981, Journal of clinical microbiology.

[146]  W. B. Sutton,et al.  IN VITRO AND IN VIVO LABORATORY STUDIES ON THE ANTITUBERCULOUS ACTIVITY OF CAPREOMYCIN , 1966, Annals of the New York Academy of Sciences.

[147]  B. Dautzenberg,et al.  Activity of clarithromycin against Mycobacterium avium infection in patients with the acquired immune deficiency syndrome. A controlled clinical trial. , 1991, The American review of respiratory disease.

[148]  R. Kanther Myambutol: chemistry, pharmacology, and toxicology. , 1970, Antibiotica et chemotherapia. Fortschritte. Advances. Progres.

[149]  F. Schmidt,et al.  Site of action of a ribosomal RNA methylase responsible for resistance to erythromycin and other antibiotics. , 1983, The Journal of biological chemistry.

[150]  S. Oldham,et al.  Clinical Presentation and Outcome of Patients with HIV Infection and Tuberculosis Caused by Multiple-Drug-resistant Bacilli , 1992, Annals of Internal Medicine.

[151]  M. L. Cohn,et al.  Some observations on the pathogenicity of isoniazid-resistant variants of tubercle bacilli. , 1953, Science.

[152]  C. Kemper,et al.  Mycobacterium Avium Complex , 2017 .

[153]  D. Snider,et al.  Rifabutin (ansamycin LM 427): a new rifamycin-S derivative for the treatment of mycobacterial diseases. , 1987, Reviews of Infectious Diseases.

[154]  G W Comstock,et al.  Epidemiology of tuberculosis. , 1982, The American review of respiratory disease.

[155]  G. Storz,et al.  Effects of peroxides on susceptibilities of Escherichia coli and Mycobacterium smegmatis to isoniazid , 1994, Antimicrobial Agents and Chemotherapy.

[156]  K. Watanabe,et al.  Synthesis and biological activity of 3'-hydroxy-5'-aminobenzoxazinorifamycin derivatives. , 1993, Chemical & pharmaceutical bulletin.

[157]  R. Wallace,,et al.  Activities of clarithromycin against eight slowly growing species of nontuberculous mycobacteria, determined by using a broth microdilution MIC system , 1992, Antimicrobial Agents and Chemotherapy.